These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 33824055

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S.
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
    Shin H, Schneeweiss S, Glynn RJ, Patorno E.
    Ann Intern Med; 2022 Jul; 175(7):927-937. PubMed ID: 35605236
    [Abstract] [Full Text] [Related]

  • 11. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME, Kosiborod M.
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study.
    Chen J, Chang J, Shi Q, Li X, Wang L, Zhao H.
    BMC Cardiovasc Disord; 2023 Oct 07; 23(1):495. PubMed ID: 37805494
    [Abstract] [Full Text] [Related]

  • 13. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.
    Wei W, Liu J, Chen S, Xu X, Guo D, He Y, Huang Z, Wang B, Huang H, Li Q, Chen J, Chen H, Tan N, Liu Y.
    Front Endocrinol (Lausanne); 2022 Oct 07; 13():850836. PubMed ID: 35330914
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
    Giugliano D, Maiorino MI, Longo M, Bellastella G, Chiodini P, Esposito K.
    Endocrine; 2019 Jul 07; 65(1):15-24. PubMed ID: 31028667
    [Abstract] [Full Text] [Related]

  • 19. Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis.
    Chen C, Peng H, Li M, Lu X, Huang M, Zeng Y, Dong G.
    Front Endocrinol (Lausanne); 2021 Jul 07; 12():664533. PubMed ID: 34759887
    [Abstract] [Full Text] [Related]

  • 20. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Banerjee M, Maisnam I, Pal R, Mukhopadhyay S.
    Eur Heart J; 2023 Oct 01; 44(37):3686-3696. PubMed ID: 37605637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.